IPSEY - Ipsen gets FDA approval for pancreatic cancer drug regimen
2024-02-13 16:38:09 ET
More on Ipsen S.A.
- Ipsen S.A. Non-GAAP EPS of €9.15, revenue of €3.13B; initiates FY24 outlook
- FDA grants priority review of Genfit-Ipsen liver disease drug
- Historical earnings data for Ipsen S.A.
- Dividend scorecard for Ipsen S.A.
- Financial information for Ipsen S.A.